Equities

Genus PLC

GNS:LSE

Genus PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2,060.00
  • Today's Change0.00 / 0.00%
  • Shares traded61.19k
  • 1 Year change2.08%
  • Beta0.3294
Data delayed at least 15 minutes, as of Oct 04 2024 16:35 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Genus PLC's revenues fell -3.03% from 689.70m to 668.80m. 33.30m to 7.90m, a -76.28% decrease.
Gross margin--
Net profit margin0.36%
Operating margin0.96%
Return on assets0.24%
Return on equity1.41%
Return on investment0.27%
More ▼

Cash flow in GBPView more

In 2024, Genus PLC increased its cash reserves by 17.08%, or 6.20m. The company earned 29.80m from its operations for a Cash Flow Margin of 4.46%. In addition the company used 19.30m on investing activities and also paid 2.80m in financing cash flows.
Cash flow per share0.749
Price/Cash flow per share27.54
Book value per share8.30
Tangible book value per share5.64
More ▼

Balance sheet in GBPView more

Genus PLC has a Debt to Total Capital ratio of 34.87%, a lower figure than the previous year's 37.90%.
Current ratio1.80
Quick ratio1.42
Total debt/total equity0.5312
Total debt/total capital0.3487
More ▼

Growth rates in GBP

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -76.34%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg)1.06%
Div growth rate (5 year)2.93%
Payout ratio (TTM)86.08%
EPS growth(5 years)-0.01
EPS (TTM) vs
TTM 1 year ago		-76.49
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.